July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Thiolated cross-linked hydrogel as a vitreous substitute – a 6-month follow-up study
Author Affiliations & Notes
  • Lisa Pohl
    Center of Ophthalmology, University Hospital Tübingen, Tübingen, Germany
  • Nele Heider
    Center of Ophthalmology, University Hospital Tübingen, Tübingen, Germany
  • Jose Hurst
    Center of Ophthalmology, University Hospital Tübingen, Tübingen, Germany
  • Martin Prinz
    Croma Pharma, Austria
  • Christine Hohenadl
    Croma Pharma, Austria
  • Charlotte Reither
    Croma Pharma, Austria
  • Kai Januschowski
    Center of Ophthalmology, University Hospital Tübingen, Tübingen, Germany
    Eye Hospital Sulzbach, Germany
  • Sven Schnichels
    Center of Ophthalmology, University Hospital Tübingen, Tübingen, Germany
  • Martin Spitzer
    University Medical Center Hamburg-Eppendorf, Germany
    Center of Ophthalmology, University Hospital Tübingen, Tübingen, Germany
  • Footnotes
    Commercial Relationships   Lisa Pohl, None; Nele Heider, None; Jose Hurst, None; Martin Prinz, Croma (I); Christine Hohenadl, Croma (E); Charlotte Reither, Croma (E); Kai Januschowski, Croma (F); Sven Schnichels, Croma (F); Martin Spitzer, Croma (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6608. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lisa Pohl, Nele Heider, Jose Hurst, Martin Prinz, Christine Hohenadl, Charlotte Reither, Kai Januschowski, Sven Schnichels, Martin Spitzer; Thiolated cross-linked hydrogel as a vitreous substitute – a 6-month follow-up study. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6608.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In the treatment of retinal detachment there is the need for a sufficient, biocompatible and biodegradable tamponade. Therefore, we evaluated the effect on the intraocular pressure (IOP), the rate of retinal detachment, fibrin and cataract induction of a thiolated cross-linked artificial vitreous body substitutes (VBS) based on hyaluronic acid (HA) in comparison to non-operated eyes in a model of tolerability.

Methods : On the right eye of 20 pigmented rabbits pars plana vitrectomy (23G) was performed. After vitrectomy of the vitreous body and fluid-air-exchange the eye was filled with the cross-linked hydrogel. The left eye served as control. Follow-up examination included slit lamp examination, funduscopy and IOP measurements. After a follow-up of 1, 3 or 6 months both eyes were removed examined macroscopically, photographed and prepared for histology.

Results : As expected, after 6 months no fibrin was detectable in the right operated eye. Over the whole follow-up period cataract induction was seen in 28% of the operated eyes. During follow-up of 6 months the eye pressure of the right eye did not show significant differences (p< 0.05) compared to the left eye and no retinal detachment was found in this group (n=6). Nevertheless, during the total follow-up period (1month, 3 months, 6 months (n=20)) there was a retinal detachment rate of 22%. Analysis of histology indicated a significant difference between the GFAP expression, but no significant difference in Brn3a (RGC-marker) expression (p<0.05).

Conclusions : In this study, the thiolated cross-linked hyaluronate hydrogel showed a high retinal attachment rate and a stable effect on the eye pressure and therefore has a promising potential as novel vitreous body substitute.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×